Synageva BioPharma Corp. (NASDAQ: GEVA)

 
Press Releases
  Date Title View
Feb 26, 2015
LEXINGTON, Mass., Feb. 26, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today reported 2014 full year financial results and provided 2015 goals, other key objectives, and financial guidance.  Synageva's management team will host a conference call today ...
PDF
Feb 25, 2015
LEXINGTON, Mass., Feb. 25, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ:GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, announced today its presentation at the upcoming Cowen and Company 35th Annual Health Care Conference in Boston, MA. Sanj K. Patel, President and Chief Executive Off...
PDF
Feb 23, 2015
LEXINGTON, Mass., Feb. 23, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Kanuma™ (sebelipase alfa) for the treatmen...
PDF
Feb 19, 2015
LEXINGTON, Mass., Feb. 19, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (Synageva) (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare diseases, will report 2014 fourth quarter and full year financial results after the NASDAQ Market closes on Thursday, February 26, 2015.  Synageva management will conduct a conferen...
PDF
Feb 18, 2015
LEXINGTON, Mass., Feb. 18, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that the European Patent Office issued European Patent No. EP2613798 B1 relating to the treatment of lysosomal acid lipase deficiency (LAL Deficiency).  This patent ...
PDF
Feb 11, 2015
LEXINGTON, Mass., Feb. 11, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today that data related to the company's programs will be the subject of three oral presentations and one poster presentation at the WORLDSymposium™ conference, Febr...
PDF
Jan 26, 2015
LEXINGTON, Mass., Jan. 26, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) has begun as part of a Phase 1/2 study.  In addition,...
PDF
Jan 6, 2015
LEXINGTON, Mass., Jan. 6, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced the pricing of its previously announced underwritten public offering of common stock consisting of 3.0 million shares at $94.19 per share.  In connection with this of...
PDF
Jan 5, 2015
LEXINGTON, Mass., Jan. 5, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced that it intends to offer for sale 2.50 million shares of its common stock in an underwritten public offering.  In connection with this offering, Synageva expects to g...
PDF
Jan 5, 2015
LEXINGTON, Mass., Jan. 5, 2015 /PRNewswire/ -- Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, announced today new pipeline programs and other company progress.  "We are building a global, generational company that will continue to make a meaningful impact on the lives...
PDF
1
...
NextLast